ReviewLeukemia2008
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
Review in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- Trial
- Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.PloS one · 2013Trial
- A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.British journal of haematology · 2009Trial
- Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.Blood advances · 2026Article
- Clonal B-Cell Lymphocytosis of Marginal Zone Origin: Presenting Features, Clinical Evolution and Prognostic Factors.Cancers · 2026Article
- [Expert consensus on the diagnosis and differential diagnosis of indolent B-cell lymphomas in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Review
- Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.Current treatment options in oncology · 2025Review
- [Clinical features and prognosis of splenic marginal zone lymphoma with POD24].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review.Recent patents on anti-cancer drug discovery · 2025Review
- CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas.Blood neoplasia · 2024Article
- Article
- The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications.Exploration of targeted anti-tumor therapy · 2024Review
- The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Review
- Unraveling the genetics of transformed splenic marginal zone lymphoma.Blood advances · 2023Article
- Follicular lymphoma and marginal zone lymphoma: how many diseases?Virchows Archiv : an international journal of pathology · 2023Review
- Management of marginal zone lymphomas.Hematology. American Society of Hematology. Education Program · 2022Article
- The Diagnostic Dilemma of Splenic Non-Hodgkin's Lymphoma and Splenic Abscess: A Narrative Review.Cureus · 2022Review
- A roadmap for clinical trial design in marginal zone lymphoma.American journal of hematology · 2022Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
Indexed as
Identifiers
18094718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.